Last reviewed · How we verify
Hydrocortisone Ophthalmic
At a glance
| Generic name | Hydrocortisone Ophthalmic |
|---|---|
| Also known as | Softacort® |
| Sponsor | Laboratorios Thea, Spain |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- Circadian Rhythmicity During Coma Awakening (NA)
- Venous Congestion And Delirium After Cardiac Surgery
- Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
- The Effect of Virtual Forest Bathing on Bariatric Surgery Patients (NA)
- Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses) (PHASE3)
- Effects of Mindfulness Meditation on Hemodialysis Patients (NA)
- Impact of Tactile Kinesthetic Stimulation and Soft Tissue Manipulation on Cortisol in Preterm (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrocortisone Ophthalmic CI brief — competitive landscape report
- Hydrocortisone Ophthalmic updates RSS · CI watch RSS
- Laboratorios Thea, Spain portfolio CI